IPO bankers are offering a lean menu for the short Thanksgiving holiday week. Only two deals – a small NYSE-AmEx listing and a big SPAC IPO – are set to price this week before the holiday. The U.S. stock market will be closed on Thursday for Thanksgiving. Wall Street will work a short half day on Friday, when both the NYSE and the NASDAQ will close at 1 p.m. EST.
Regentis Biomaterials, Ltd. (RGNT Proposed) expects to price its small IPO on Tuesday night, Nov. 25, 2025, to trade Wednesday on the NYSE – AmEx. The deal consists of just 1 million shares – at a price range of $10.00 to $12.00 – to raise $11 million, if priced at the mid-point of its range.
ThinkEquity is the sole book-runner.
Based in Herzliya, Israel, Regentis Biomaterials is a regenerative medicine company developing orthopedic hydrogel implants to repair painful injuries to the knee cartilage. Its lead product candidate, GelrinC, is a degradable hydrogel implant to regenerate damaged or diseased tissue. GelrinC was approved as a device with a CE mark in Europe in 2017. The company plans to identify strategic partners in Europe to bring its product to market, the prospectus said.
“Because GelrinC serves as an impenetrable barrier that stops cells from migrating away from the wound’s edges, we believe our product is the only product that helps to regenerate cartilage inwards from the edges of the cell walls,” Regentis Biomaterials said in the prospectus.
The company is not profitable, according to financial statements in the prospectus.
SC II Acquisition (SCIIU Proposed) plans to price its SPAC IPO – 15 million units at $10.00 each – to raise $150 million on Tuesday night, Nov. 25, 2025. This is a NASDAQ listing. Each unit consists of one share of stock and one right to receive one-fifth (1/5) of a share upon the completion of an initial business combination.
D. Boral Capital (ex-EF Hutton) is the sole book-runner.
SC II Acquisition, based in New York, has not chosen a sector or a geographic region as its focus.
Menachem Shalom has served as its CEO since inception. Since January 2025, Shalom has also been the CEO and a director of Kochav Defense Acquisition Corp. (NASDAQ: KCHVU), a SPAC that completed its $253 million initial public offering in May 2025. Kochav Defense Acquisition is seeking a business combination target in the defense and aerospace industries.
Stay tuned.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading